Streetbeat News

Analyst Ratings

ASML

Benzinga's options scanner revealed significant options activity for ASML Holding (NASDAQ:ASML), indicating deep-pocketed investors' interest. The sentiment is mixed with 57% bullish and 42% bearish. Notable options activity includes 7 puts and 7 calls with a price window from $750 to $960. ASML is a leader in photolithography systems for semiconductor manufacturing, with main clients like TSMC, Samsung, and Intel. The stock is currently neutral with an RSI indicator and is down -0.69% at $863.06. Analysts from Raymond James have set price targets of $1000 and $850, maintaining a Strong Buy rating. Options trading involves higher risks and rewards, and traders are advised to stay informed.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 2:46 pm

ASB

RBC Capital analyst Jon Arfstrom has maintained a 'Sector Perform' rating on Associated Banc-Corp (NYSE:ASB) and increased the price target from $22 to $23.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:45 pm

KLAC

Goldman Sachs analyst Toshiya Hari has reaffirmed a Buy rating on KLA Corporation (NASDAQ:KLAC) and increased the price target from $560 to $640.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:44 pm

BHLB

RBC Capital analyst Jon Arfstrom has reiterated a 'Sector Perform' rating on Berkshire Hills Bancorp (NYSE:BHLB) and maintained a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:41 pm

INTC

Goldman Sachs analyst Toshiya Hari has maintained a Sell rating on Intel Corporation (NASDAQ:INTC) but increased the price target from $34 to $39.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:41 pm

CVE

RBC Capital analyst Greg Pardy has reiterated an Outperform rating on Cenovus Energy, maintaining a price target of C$28. The company is listed on the Toronto Stock Exchange under the symbol TSX:CVE.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:37 pm

IDYA

Goldman Sachs analyst Corinne Jenkins has reaffirmed a Buy rating on IDEAYA Biosciences (NASDAQ:IDYA) and increased the price target from $36 to $53, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:35 pm

HUM

Goldman Sachs analyst Nathan Rich has maintained a Buy rating on Humana (NYSE:HUM) but has reduced the price target from $515 to $450.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:30 pm

OMAB

Goldman Sachs analyst Bruno Amorim has reaffirmed a Buy rating on Central North Airport Gr (NASDAQ:OMAB) and increased the price target from $79 to $94, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:29 pm

FULC

Goldman Sachs analyst Madhu Kumar has maintained a Neutral rating on Fulcrum Therapeutics (NASDAQ: FULC) and increased the price target from $5 to $6.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:28 pm